Extragonadal FSHRs, which include bone (23, 24), monocytes (25, 26), different sites of the female reproductive tract and the developing placenta (27), endothelial cells from umbilical vein (28) and blood vessels from malignant tumors and metastases (29–31), and the liver (32), have been identified employing different detection approaches, mainly immunohistochemistry and more recently in vitro and in vivo imaging of FSH-conjugated NIRII-fluorophore (33). Here, BRD2 is linked to cancer.